Gamida Cell to Report Third Quarter 2023 Financial Results
Following the release, management will host a conference call and live webcast at 8:30 am Eastern Time to discuss the financial results, provide business updates and answer questions.
Conference Call Dial-In & Webcast Information:
|Call me™:||Click here.|
A replay of the webcast will be available on the Company’s website. approximately two hours after the event, for approximately 30 days.
About Gamida Cell
Gamida Cell is a cell therapy pioneer working to turn cells into powerful therapeutics. The company’s proprietary nicotinamide (NAM) technology leverages the properties of NAM to enhance and expand cells, creating allogeneic cell therapy products and candidates that are potentially curative for patients with hematologic malignancies. These include Omisirge™ (omidubicel-onlv), an FDA-approved nicotinamide modified allogeneic hematopoietic progenitor cell therapy for patients with hematologic malignancies, and GDA-201, an intrinsic NK cell therapy candidate being investigated for the treatment of patients with non-Hodgkin lymphoma. For additional information, please visit www.gamida-cell.com or follow GamidaCell on LinkedIn, X, Facebook or Instagram.
Omisirge™ is a trademark of Gamida Cell Inc. © 2023 Gamida Cell Inc. All Rights Reserved.
Source: Gamida Cell, Ltd